International collaboration and a shared vision are key to improving cancer patients’ lives
The 2025 ESMO Lifetime Achievement Awardee, Prof. Rolf Stahel, reflects on the role of the oncology community to drive progress in cancer care
How will computational and AI tools guide future anticancer strategies?
Growing evidence shows that AI models can predict a patient's disease trajectory and signal the need for early therapeutic intervention
Mentoring is key to address the gender gap in oncology
Receiving the 2025 ESMO Women for Oncology Award, Dr Natasha Leighl stresses the importance of passing along learnings, support and opportunities to others
ESMO confers a new award on pioneer female oncologist in Ecuador
Glenda Ramos Martínez receives the ESMO Oncologist of the Year Award, launched this year by the Society
The long road toward treatment personalisation for pancreatic and rectal cancers
The 2025 ESMO Awardee, Thierry Conroy, traces the major advances in the field while noting that several barriers to improving patient outcomes remain
Optimising cancer care for individual patients is key to improving outcomes for all
An ESMO roadmap addresses how the new challenges in oncology can be transformed into opportunities for the benefits of oncology professionals and patients with cancer
Personalising cancer treatment with AI and digital pathology
Leveraging artificial intelligence and digital pathology, oncology is entering a transformative stage where advanced image analysis and AI-driven biomarkers enable personalised cancer treatment decisions.
Status and trends in digital pathology
Pathology is going digital. More than 50 AIs cleared for diagnostic use are now available. This article summarises the status quo and gives an outlook of upcoming emerging technologies.
How you can do your part in the AI transformation of oncology
An interview with ESMO President Prof. Fabrice André underscores the importance for any medical oncologist of developing artificial intelligence literacy
Study presents an AI-guided approach to target cancer antigens
The innovative approach was successfully tested on NY-ESO-1 and promises to bypass some current challenges in the identification of T cell receptors for therapeutic use